![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Prostate Cancer |
Free Subscription
2 BMC Urol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Prostate Cancer is free of charge.
Association of metabolic syndrome and its components with the risk of urologic
cancers: a prospective cohort study.
BMC Urol. 2023;23:150.
PubMed
Abstract available
Patient's safety and satisfaction on same day discharge after robotic and
laparoscopic radical prostatectomy versus discharge after 24 or 48 h: a
longitudinal randomized prospective study.
BMC Urol. 2023;23:149.
PubMed
Abstract available
Biopsy-free AI-aided precision MRI assessment in prediction of prostate cancer
biochemical recurrence.
Br J Cancer. 2023 Sep 27. doi: 10.1038/s41416-023-02441.
PubMed
Abstract available
Prospective inter- and intra-tracer repeatability analysis of radiomics features
in [(68)Ga]Ga-PSMA-11 and [(18)F]F-PSMA-1007 PET scans in metastatic prostate
cancer.
Br J Radiol. 2023 Sep 26:20221178. doi: 10.1259/bjr.20221178.
PubMed
Abstract available
Relative fat fraction of malignant bone lesions from breast cancer, prostate
cancer and myeloma are significantly lower than normal bone marrow and shows
excellent interobserver agreement.
Br J Radiol. 2023 Sep 26:20230240. doi: 10.1259/bjr.20230240.
PubMed
Abstract available
The utility of [(18)F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate
Resistant Prostate Cancer Patients (nmCRPCp): Diagnostic performance and Impact
on Management.
Br J Radiol. 2023 Sep 26:20230414. doi: 10.1259/bjr.20230414.
PubMed
Abstract available
SpaceOAR hydrogel complications in prostate cancer: Pictorial review.
Br J Radiol. 2023 Sep 26:20230717. doi: 10.1259/bjr.20230717.
PubMed
Abstract available
Are T2WI PI-RADS sub-scores of transition zone prostate lesions biased by DWI
information? A multi-reader, single-center study.
Eur J Radiol. 2023;167:111026.
PubMed
Abstract available
MA-QC: Free online software for prostate MR quality control and PI-QUAL
assessment.
Eur J Radiol. 2023;167:111027.
PubMed
Abstract available
Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the
USA from 2010 to 2020: Insights from the National Cancer Data Base.
Eur Urol. 2023 Sep 25:S0302-2838(23)03088-9. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical
Trial. Eur Urol 2023
Eur Urol. 2023 Sep 25:S0302-2838(23)03094-4. doi: 10.1016/j.eururo.2023.
PubMed
Reply to Andre Pontes-Silva's Letter to the Editor re: Gabriela Ilie, Ricardo
Rendon, Ross Mason, et al. A Comprehensive 6-mo Prostate Cancer Patient
Empowerment Program Decreases Psychological Distress Among Men Undergoing
Curative Prostate Cancer Tr
Eur Urol. 2023 Sep 22:S0302-2838(23)03091-9. doi: 10.1016/j.eururo.2023.
PubMed
Re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Undergoing Curative Prostate Cancer Treatment: A Randomized Clinical
Trial. Eur Urol 2023
Eur Urol. 2023 Sep 22:S0302-2838(23)03095-6. doi: 10.1016/j.eururo.2023.
PubMed
Re: MRI-Detectability of Clinically Significant Prostate Cancer Relates to
Oncologic Outcomes After Prostatectomy.
Eur Urol. 2023 Sep 22:S0302-2838(23)03080-4. doi: 10.1016/j.eururo.2023.
PubMed
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging
and Theranostics in Prostate Cancer.
Eur Urol. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.
PubMed
Abstract available
Reply to Matthias May, Ingmar Wolff, and Sabine D. Brookman-May's Letter to the
Editor re: Gabriela Ilie, Ricardo Rendon, Ross Mason, et al. A Comprehensive 6-mo
Prostate Cancer Patient Empowerment Program Decreases Psychological Distress
Among Men Un
Eur Urol. 2023 Sep 22:S0302-2838(23)03093-2. doi: 10.1016/j.eururo.2023.
PubMed
Salvage Radiation Therapy After Radical Prostatectomy: Analysis of Toxicity by
Dose-Fractionation in the RADICALS-RT Trial.
Int J Radiat Oncol Biol Phys. 2023;117:624-629.
PubMed
Abstract available
A Novel Ultrahigh-Dose-Rate Proton Therapy Technology: Spot-Scanning Proton Arc
Therapy + FLASH (SPLASH).
Int J Radiat Oncol Biol Phys. 2023;117:730-737.
PubMed
Abstract available
An Intrapatient Dosimetry Comparison of (177)Lu-rhPSMA-10.1 and (177)Lu-PSMA-I&T
in Patients with Metastatic Castration-Resistant Prostate Cancer.
J Nucl Med. 2023 Sep 28:jnumed.123.265970. doi: 10.2967/jnumed.123.265970.
PubMed
Abstract available
PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients
with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen
Receptor Pathway Inhibitors.
J Nucl Med. 2023 Sep 28:jnumed.123.265874. doi: 10.2967/jnumed.123.265874.
PubMed
Abstract available
Epithelial specific splicing regulator proteins as emerging oncogenes in
aggressive prostate cancer.
Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
PubMed
Abstract available
A novel rapid detection method for a single-nucleotide substitution mutation
derived from canine urothelial and prostatic carcinoma cells present in small
amounts in urine sediments.
PLoS One. 2023;18:e0286229.
PubMed
Abstract available
[Oncological and functional results of focal treatment of localized prostate
cancer with HIFU].
Prog Urol. 2023 Sep 26:S1166-7087(23)00215-4. doi: 10.1016/j.purol.2023.
PubMed
Abstract available
Polyphyllin I induces ferroptosis in castration-resistant prostate cancer cells
through the ERK/DNMT1/ACSL4 axis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24626.
PubMed
Abstract available
The diagnostic accuracy of (68) Ga-PSMA-PET/CT in primary staging of patients
with high-risk nonmetastatic prostate cancer treated with radical prostatectomy:
A single-center cohort analysis.
Prostate. 2023 Sep 26. doi: 10.1002/pros.24627.
PubMed
Abstract available
Development and internal validation of a nomogram predicting significant prostate
cancer: Is it clinically applicable in low prevalent prostate cancer countries? A
multicenter study.
Prostate. 2023 Sep 27. doi: 10.1002/pros.24625.
PubMed
Abstract available
MRI for detection, staging, and follow-up of prostate cancer: Synthesis of the
PI-RADS v2.1, MET-RADS, PRECISE, and PI-RR guidelines.
Radiologia (Engl Ed). 2023;65:431-446.
PubMed
Abstract available
Deep Learning Super-Resolution Reconstruction for Fast and Motion-Robust
T2-weighted Prostate MRI.
Radiology. 2023;308:e230427.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by